3 / 27
TKR
IC
50
(nmol/L)
Sorafenib
Lenvatinib
VEGFR-1
21
4.7
VEGFR-2
21
3
VEGFR-3
16
2.3
FGFR1
340
61
FGFR2
150
27
FGFR3
340
52
FGFR4
3400
43
PDGFRα
1.6
29
PDGFR
b
27
160
c-KIT
140
85
RET
15
6.4
c-KIT = receptor for stem cell factor; c-MET = proto-oncogene for hepatocyte growth factor receptor; FGF = fibroblast growth factor; FGFR = fibroblast growth factor receptor; HCC =
hepatocellular carcinoma; IC
50
= 50% inhibitory concentration; LEN = lenvatinib; PDGFR = platelet-derived growth factor receptor; REGO = regorafenib; RET = rearranged during
transfection; SORA = sorafenib; TKR = tyrosine kinase receptor; VEGF = vascular endothelial growth factor;
VEGFR = vascular endothelial growth factor receptor.
1. Tohyama O
et al
.
J Thyroid Res.
2014;2014:638747.
SORA
REGO
LEN
HCC
endothelial cell
VEGFR2 FGFR1
VEGF
P
P
FGFs
Angiogenesis
HCC
tumor cell
FGFR1-3
FGFs
FGFR4
P
P
Survival/Growth
FGF19
LEN
Lenvatinib’s Dual Inhibition of VEGF and FGF Pathways